Steven M. Paul, Director at Sage Therapeutics, Inc. (SAGE), sold 20,000 shares at $67.98 ($1.3M) on 2015-08-03, disclosed to the SEC on 2015-08-04.
Scheduled sale ($1.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.42 | 6,020 | $400K | 29.8% |
| 2 | $67.05 | 9,158 | $614K | 45.8% |
| 3 | $67.98 | 4,822 | $328K | 24.4% |
| Total | $67.08 avg | 20,000 | $1.3M | 100% |
| Filing → |
| KRTX | BUY | 2021-08-18 | $501K | — | Filing → |
| ALNY | SELL | 2020-12-22 | $2.1M | — | Filing → |
| KRTX | SELL | 2020-06-30 | $60.5M | — | Filing → |